生物制剂降低类风湿关节炎患者全膝与全髋置换风险
这项基于2000-2013年台湾全民健康保险理赔数据库的回顾性全国研究,比较了生物制剂队列与年龄性别匹配的csDMARD队列的TKR和THR风险。结果显示生物制剂队列TKR和THR发生率显著更低,校正混杂后规律使用bDMARD(平均剂量>0.95 defined daily dose/day)者TKR风险aHR 0.55(95%CI 0.38,0.81)、THR风险aHR 0.63(95%CI 0.40,0.98)。
要点
- 生物制剂队列TKR发生率11.73 vs 16.33/1000人年,THR发生率7.09 vs 9.16/1000人年,均P<0.001。
- 规律使用bDMARD者TKR风险aHR 0.55(95%CI 0.38,0.81),THR风险aHR 0.63(95%CI 0.40,0.98)。
- 未用MTX、使用激素、生物制剂转换及重叠抗磷脂综合征者TKR和THR风险显著更高。
核心结论
- 与csDMARD队列相比,bDMARD队列中低至中等剂量亚组的TKR和THR风险与csDMARD队列相同,而规律使用bDMARD者风险显著更低。
研究设计与样本
- 回顾性全国性研究,使用2000-2013年理赔型全民健康保险数据库,生物制剂队列与年龄性别匹配的csDMARD队列比较。
主要发现
- 生物制剂队列TKR发生率显著更低(11.73 vs 16.33/1000人年,P<0.001)。
- 生物制剂队列THR发生率显著更低(7.09 vs 9.16/1000人年,P<0.001)。
- 校正混杂后,规律bDMARD亚组(平均剂量>0.95 defined daily dose/day)TKR风险aHR 0.55(95%CI 0.38,0.81),THR风险aHR 0.63(95%CI 0.40,0.98)。
关键数值与推荐
- 规律bDMARD使用定义为平均剂量>0.95 defined daily dose/day。
- 未用MTX、使用激素、生物制剂转换及重叠抗磷脂综合征者TKR和THR风险显著更高。
临床怎么用
- 对于难治性RA患者,规律使用bDMARD可能降低全膝和全髋置换风险。
- 未用MTX、使用激素、生物制剂转换及重叠抗磷脂综合征者需关注关节置换风险。
局限性
- 本研究为回顾性理赔数据库研究,可能存在混杂因素。
- 生物制剂仅覆盖难治性病例,存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: RA damages the joints and increases the risks of total knee replacement (TKR) and total hip replacement (THR). However, the benefits of biologics in preventing TKR or THR remain unclear. METHODS: This retrospective nationwide study used the 2000-2013 claims-based National Health Insurance dataset. Biologics are reimbursed for refractory cases. The risks of TKR and THR in the biologic cohort were compared with those of an age- and sex-matched csDMARD cohort. A multivariate Cox regression model was used to investigate the benefits of bDMARDs for TKR and THR. RESULTS: TKR was performed in 5979 biologic cases and 11 958 matched controls, of which 249 (4.16%) and 871 (7.28%) cases received TKR, respectively. THR was performed in 6245 biologic cases and 12 490 matched controls, of which 159 (2.55%) and 516 (4.13%) cases had THR, respectively. The biologic cohort had significantly lower incidence rates of TKR (11.73 vs 16.33/1000 person-years, P < 0.001) and THR (7.09 vs 9.16/1000 person-years, P < 0.001). After adjustment for confounding factors, the regular bDMARD subgroup (average dose >0.95 defined daily dose/day) had significantly lower risks of TKR (aHR: 0.55, 95% CI: 0.38, 0.81) and THR (aHR: 0.63, 95% CI: 0.40, 0.98). Those without MTX use, with steroid use, with biologic switch, and overlapping antiphospholipid syndrome had significantly higher risks of TKR and THR. CONCLUSIONS: Compared with the csDMARD cohort, the risks of TKR and THR in the bDMARD cohort were the same as those in the low-to-moderate dose subgroups and significantly lower in those with regular bDMARD use.
引用
- Chang YS, Chen JH, Lin TM, et al. Effects of biologics on reducing the risks of total knee replacement and total hip replacement in rheumatoid arthritis. Rheumatology (Oxford). 2022. PMID: 34534283. doi:10.1093/rheumatology/keab671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。